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Prevalence of Different Gadolinium Enhancement
Patterns in Patients After Heart Transplantation
Henning Steen, MD, Constanze Merten, MD, Sonja Refle, MD, Roland Klingenberg, MD,
Thomas Dengler, MD, Evangelos Giannitsis, MD, Hugo A. Katus, MD
Heidelberg, Germany
Objectives Transplant coronary artery disease (TCAD) limits long-term survival after heart transplantation (HTX). We hypoth-
esized that contrast-enhanced magnetic resonance imaging (CE-MRI) detects chronic TCAD-related myocardial
infarctions (MIs), even in patients with angiographically classified mild TCAD.
Background Coronary angiography underestimates the TCAD-degree, subsequently missing occluded small coronary arteries
and resulting MI. CE-MRI as a noninvasive imaging technique identifies infarct-typical MI and myocardial fibrosis.
Methods CE-MRI (gadolinium: 0.2 mmol/kg/bw) was performed in 53 HTX patients on a 1.5-T MRI scanner (Philips,
Best, the Netherlands). Infarct-typical CE-MRI areas were classified as: I  25%, II  25% to 50%, III 
50% to 75% and IV  75%. Infarct-atypical forms were divided into diffuse, spotted, intramural, and
infero-septal. Coronary angiography results were reviewed qualitatively with the TCAD score (TCAD I  mild
evidence; II  30% to 75%, III  75% stenosis). Groups were compared with analysis of variance (statisti-
cally significant p values 0.05).
Results Infarct-typical CE-MRI was already present in TCAD I  II, increased significantly between groups (I  23%,
II  33%, III  84%, p  0.05), and involved only single coronary territories in TCAD I but multiple vessels
in TCAD II  III. Infarct-atypical CE-MRI was equally distributed across all TCAD stages (I  50% vs. II 
58% vs. III  42%, p  NS) without relation to a coronary territory. Patients with only infarct-atypical CE-
MRI were associated with significantly better left ventricular function compared with patients with infarct-
typical or combined CE-MRI patterns (ejection fraction  66  6% vs. 45  16% or 60  13%; end-
diastolic volume  139  32 ml vs. 148  27 ml or 164  43 ml; end-systolic volume  47  15 ml vs.
81  27 ml or 69  38 ml, p  0.05).
Conclusions CE-MRI allows identification of silent MI in apparently event-free HTX patients and is able to disclose myocardial
fibrosis already in patients with absent or mild angiographic TCAD. CE-MRI might be helpful to establish an ear-
lier TCAD diagnosis and to intensify medical treatment. Future studies are necessary to test prognostic implica-
tions associated with CE-MRI patterns. (J Am Coll Cardiol 2008;52:1160–7) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.059v
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feart transplantation (HTX) is the ultimate therapy for
atients with end-stage heart failure. Worldwide, nearly
,000 patients receive HTX/year (1). Knowledge of pre-
perative and post-operative medical treatment and man-
gement as well as improvement in surgical techniques has
ncreased tremendously in the last 2 decades, resulting in
mproved graft survival and patient outcome (1,2).
Nowadays, chronic sequels such as interstitial myocardial
brosis due to immunosuppressive therapy as well as ele-
rom the Abteilung Innere Medizin III, Medizinische Klinik, Universitätsklinikum
eidelberg, Heidelberg, Germany. The authors had full access to the data and take
esponsibility for its integrity. All authors have read and agree to the article as written.
rs. Steen and Merten contributed equally to this work.t
Manuscript received November 13, 2007; revised manuscript received March 3,
008, accepted May 21, 2008.ated immune-activated vascular atherosclerosis, also called
ransplant coronary artery disease (TCAD), play a more
dvanced role in the aftercare of HTX (3).
See page 1168
TCAD is an allograft pan-arterial disease characterized
y diffuse concentric and longitudinal intima hyperplasia
ffecting the entire graft coronary artery vasculature and is
ssociated with major adverse cardiac events (4). The
eference standard for TCAD detection is intravascular
ltrasound (IVUS) (5), but due to high cost and the limited
vailability of IVUS, coronary angiography (fluoroscopy) is
sually performed (6). Consequently, subclinical TCAD is
requently overlooked, and patients do not receive adequate
herapy. Furthermore, standard angiography lacks informa-
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rosclerosis (7,8).
Additionally, routine annual medical HTX assessment
ncluding invasive coronary fluoroscopy exposes patients to a
ubstantial radiation dose and to the hazard of nephro-toxic
ontrast agents (9). Another inherent problem of fluoros-
opy angiography is the lack of tissue information, making
otentially hazardous myocardial biopsies necessary for the
stimation of commencing tissue rejection processes or
yocardial fibrosis (10).
To circumvent these shortcomings in stagingHTX patients,
noninvasive approach with advanced tissue characterization
ould be a helpful tool (11).
Magnetic resonance imaging (MRI) is a noninvasive and
onradiation imaging technique offering excellent tissue
ontrast and superior image quality (12).
By administration of gadolinium contrast agents in com-
ination with specific MRI imaging sequences, delayed
ontrast-enhanced (CE) MRI enables further high-
esolution tissue characterization. Intramural, diffuse, or
ubepicardial infarct-atypical versus acute or chronic infarct-
ypical subendocardial fibrosis with various degrees of trans-
urality can be distinctly differentiated (13).
In the present study we sought to apply CE-MRI to
nvestigate its feasibility to assess the prevalence of infarct-
ypical and -atypical myocardial fibrosis in patients after
TX. We further hypothesized that in patients with
uoroscopy classified mild TCAD we would already detect
ither chronic infarct-typical or -atypical or a combination
f CE-MRI patterns and could therefore further subclassify
TX patients on a tissue level.
ethods
tudy population. From October 2004 until December
005 we studied 53 consecutive asymptomatic adult HTX
atients, including 42 men and 11 women. The study was
pproved by the institutional review committee, and pa-
ients gave informed consent.
oronary angiography. Coronary angiography was per-
ormed by the femoral approach with standard fluid-filled
atheters within 4 weeks of MRI scans. All patients under-
ent right and left heart catheterization and endomyocar-
ial biopsy. Angiograms were obtained from multiple pro-
ections and interpreted qualitatively by 2 independent
bservers blinded to the MRI data analysis.
ngiographic classification of TCAD. Angiographic es-
imation of allograft TCAD in epicardial coronary arteries
as semi-quantitatively standardized with the following
riteria: Imild evidence of TCAD, IImanifest TCAD
ith focal lesions 30% to 75% stenosis, and III  severe
CAD with focal lesions 75% or need for interventional
reatment.
ejection score and rejection treatment/year score. Rou-
ine endomyocardial biopsies were performed on an annual dasis. Cardiologists and cardiol-
gy fellows performed all biop-
ies; experienced cardiac pathol-
gists reviewed and graded the
iopsy specimens according to In-
ernational Society for Heart and
ung Transplantation (ISHLT)
riteria (14). A rejection index was
alculated as follows: ISHLT re-
ection grades were assigned a
oint score (ISHLT 0/1A 1⁄4  0
oints, 1B 1⁄4 1 point, 2 1⁄4 2
oints, 3A 1⁄4  3 points, 3B 1⁄4
4 points, and 4 1⁄4  5 points).
he total point score of all biopsy
esults of a patient was normalized
o the number of biopsies per-
ormed to yield the rejection index.
RI protocol. Within 4 weeks
f coronary angiography, vector-
lectrocardiography–triggered
E-MRI was performed on a
.5-T Whole Body MRI scanner
Philips Medical Systems, Best,
he Netherlands) with a cardiac
hased-array receiver coil.
Assessment of left ventricular (LV) function and late
nhancement (CE-MRI) was performed in a standardized
ay (15,16) with the following amendments: 10 to 15 min
fter a dose of 0.2 mmol gadolinium per kilogram of body
eight (Magnevist, Schering, Germany), a 3-dimensional
equence with inversion time (TI) scout was used to select
he TI, which was typically 180 to 240 ms.
RI data analysis. An MRI wall motion and contrast
nhancement data analysis was carried out on a commer-
ially available cardiovascular magnetic resonance worksta-
ion (Philips Viewforum, Version 3.4). Two blinded observ-
rs conducted image analysis at least 8 weeks after
cquisition. For CE-MRI data analysis, the accredited
merican Heart Association (AHA) 17-segment model
17) of the LV was employed.
End-diastolic volume (EDV) (milliliters) and end-
ystolic volume (ESV) (milliliters) with resulting ejection
raction (EF) (%) were generated manually with short-axis
olumetry by determination of end-diastolic and -systolic
eart phases and subsequent delineation of endocardial
orders excluding papillary muscles.
For evaluation of myocardial mass, borders were drawn at
he interface between myocardium and epicardium on
nd-diastolic images including papillary muscles.
E-MRI. Before analysis, 2 readers classified CE-MRI
mage quality into diagnostically analyzable or qualitatively
nacceptable.
Accordingly, images were divided into infarct-typical
right lesions with subendocardial involvement and variable
Abbreviations
and Acronyms
CE-MRI  contrast-
enhanced magnetic
resonance imaging
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
HTX  heart
transplantation
ISHLT  International
Society for Heart and Lung
Transplantation
IVUS  intravascular
ultrasound
LV  left ventricular
MI  myocardial infarction
NT-proBNP  N-terminal
part of the pro-B-type
natriuretic peptide
TCAD  transplant
coronary artery disease
TI  inversion timeegrees of transmurality. In contrast, less distinct intramyo-
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MRI Characterization of Patients After HTX September 30, 2008:1160–7ardial or epimyocardial patchy or nodular enhancing areas
mitting the subendocardium were classified as atypical
E-MRI (Fig. 1).
Qualitative infarct size was visually assessed per segment
nd classified as grade I  25%, grade II  26% to 50%,
rade III  51% to 75%, and grade IV  75% of LV wall
hickness.
For quantitative infarct size analysis, we employed a
pecific scar measurement tool (Philips Viewforum), where
nfarct size was visually defined as area of CE-MRI on
hort-axis views. Infarct size was determined visually and
rawn manually by delineation of hyperenhanced versus
ormally saturated dark myocardium. Volume integration
f hyperenhanced areas on short-axis slices were consid-
red as absolute infarct masses.
Mean mass of CE-MRI for TCAD I to III was normal-
zed to mean myocardial mass/TCAD group and is given in
ercent infarcted mass/normal myocardium.
To prove the existence of atypical enhancement we also
epeated basal, mid-ventricular, and apical inversion recov-
ry 2-dimensional short-axes (inversion recovery prepared
urbo field echo, pixel size 1.8 1.4 mm, slice thickness
mm) MRI with higher resolution with 2 phase-encoding
irections to exclude artefact (16) after adjustment of the
orrect TI time (180 to 240 ms) (18).
Figure 1 Distribution and Percentage of Murality of Myocardial
Infarct-typical (A, B) and -atypical (C to F) contrast-enhanced magnetic resonanceegional CE-MRI distribution and functional assess-
ent of infarct-typical and -atypical enhancement pat-
erns. Myocardial areas of infarct-typical and -atypical
E-MRI were allocated to the AHA 17-segment model
18) to further investigate potential differences in regional
istribution patterns.
tatistics. All continuous variables were expressed as mean
D. Medians are given with the 25%/75% confidence inter-
als. Comparison of groups was conducted with analysis of
ariance statistics. For nonparametric variables we used
ither the Kruskal-Wallis or the chi-square test for di-
hotomic variables. A p value 0.05 was considered statis-
ically significant.
esults
tudy population. We divided our patients into 3 groups
TCAD I to III) following the angiographic criteria.
atient characteristics are shown in Table 1.
Patient age (years), gender, and body mass index
kg/m2) were not notably different. Patients with TCAD
II were transplanted significantly longer ago than
CAD I  II patients (p  0.001). Ischemia time of the
ransplanted hearts was significantly different among all 3
roups (p  0.001). Interestingly, TCAD III patients
ad the shortest ischemia time. The rejection score and
ctions in Transplant Coronary Artery Disease I to III
g patterns. The red arrows point to the contrast-enhanced lesions.Infar
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September 30, 2008:1160–7 MRI Characterization of Patients After HTXejection treatment/year score as well as heart recipient
ardiovascular risk factors were also not significantly
issimilar.
When compared with TCAD I  II patients, recipi-
nts with TCAD III had significantly lower EF (49 
3% vs. 64  10% vs. 64  10%, p  0.01), higher ESV
85  34 ml vs. 50  18 ml vs. 56  18 ml, p  0.01),
nd lower cardiac output (5.8  1.4 ml vs. 7.1  1.7 ml
atient Characteristics
Table 1 Patient Characteristics
TCAD I
Heart recipient
Number of patients 28
Gender (% female) 6 (21%)
BMI (kg/m2) 25.7 4.8
Age (yrs) 57 11.6
Years after HTX 5.8 4.5
Rejection score 0.3 0.3
Ischemia time of TX heart (min) 170 52
Heart recipient cardiovascular risk factors
Hypertension 16 (57%)
Diabetes 6 (25%)
LDL (mg/dl) 102.7 22.4
HDL (mg/dl) 57.1 11.3
Cytomegalie virus infection 9 (32%)
Heart recipient basic heart parameters
Heart rate 81.2 11.1
EF (%) 63.7 9.8
EDV (ml) 139.0 26.1
ESV (ml) 50.2 18.2
CO (l/min) 7.1 1.7
SV (ml) 83.8 24.0
Mass (g) 100.5 27.6
Heart recipient serum parameters
cTnT pts with elevated levels 3 (10%)
cTnT (ng/dl) 0.01 0.03
NT-proBNP pts with 125 ng/l levels (%) 24 (86%)
Median NT-proBNP (mg/dl) (25%–75% percentiles) 537 (160–1,106
Creatinine pts with elevated levels 1.5 mg/dl (%) 27 (96%)
Creatinine (mg/dl) 1.4 0.6
Concomitant diseases
ESRD 22
Peripheral artery disease 3
COPD 3
Monoclonal immunoglobulinopathy 2
Osteoporosis/osteopenia 2
Heart donor
Donor age 35.0 12.2
Donor gender (% female) 15 (54%)
Indications for heart transplantation
DCM 16
Ischemic cardiomyopathy 9
Valvular cardiomyopathy 1
Constrictive pericarditis 1
Myocarditis 1
MI body mass index; CO cardiac output; COPD chronic obstructive pulmonary disease; cTnT
SRD  end stage renal disease; ESV  end-systolic volume; HDL  high-density lipoprotein; HTX
atriuretic peptide; pts patients; TCAD I no evidence of TCAD; TCAD II established TCAD withs. 7.8  1.4 ml, p  0.01), whereas baseline heart rate, TDV, stroke volume, and myocardial mass were not
ignificantly different.
The N-terminal part of the pro-B-type natriuretic pep-
ide (NT-proBNP) levels in all 3 groups were significantly
levated (cut-off value 125 ng/l) and differed significantly.
oreover, between 80% and 93% of the patients showed a
hronic renal impairment (creatinine levels 1.5 mg/dl)
ith no significantly different creatinine levels between
TCAD II TCAD III p Value
15 10
2 (13%) 3 (30%)
27.2 3.4 25.0 4.3 NS
53.9 12.7 61.0 10.8 NS
6.5 3.8 11.9 4.5 0.001
0.3 0.3 0.3 0.2 NS
194 46 157 34 0.001
13 (87%) 5 (50%) NS
2 (13%) 5 (50%) NS
95.2 19.5 95.2 18.7 NS
51.0 9.8 51.0 8.3 NS
4 (27%) 1 (10%) NS
82.0 12.3 74.0 14.1 NS
63.6 10.2 48.8 13.3 0.01
152.7 23.2 167.6 44.9 NS
55.6 18.1 85.1 44.9 0.01
7.8 1.4 5.8 1.4 0.01
97.1 21.5 78.5 24.6 NS
102.7 24.5 110.4 27.8 NS
1 (7%) 4 (40%)
0.01 0.05 0.02 0.03 NS
13 (87%) 10 (100%)
643 (235–1,009) 2,505 (680–4,273) 0.001
12 (80%) 9 (90%)
1.5 0.9 1.7 0.6 NS
8 5 NS
0 0 NS
2 2 NS
0 3 NS
2 0 NS
36.9 11.9 41.4 14.9 NS
5 (33%) 7 (70%)
11 6
3 3
1 0
0 0
0 1
iac troponin T; DCM dilated cardiomyopathy; EDV end-diastolic volume; EF ejection fraction;
rt transplantation; LDL  low-density lipoprotein; NT-proBNP  N-terminal part of the pro-B-type
75% stenosis; TCAD III severe TCAD with lesions75% or need for interventional treatment.)
 cardCAD I to III patients.
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MRI Characterization of Patients After HTX September 30, 2008:1160–7RI results. After consensus reading of 2 experienced
nalysts, CE-MRI image quality was acceptable in 22 of 28
CAD I (79%), 12 of 15 TCAD II (80%), and 7 of 10
CAD III (70%) patients. The reasons for the 12 unac-
eptable CE-MRI scans were as follows: 1) nonspecified
rrhythmia (5); 2) inadequate electrocardiography-triggering
6); 3) commencing hyperventilation; and/or 4) claus-
rophobia during the study.
E-MRI patterns. Figure 1 indicates the different pat-
erns of CE-MRI in HTX patients. Figures 1A and 1B
resent an infarct-typical small focal and large trans-
ural myocardial infarction (MI).
Morphologically, 4 different forms of infarct-atypical
adolinium accumulations could be distinguished: diffuse
esions with patchy and transmural CE-MRI (Fig. 1C);
potted, more sharply distinguishable intramural bright
esions (Fig. 1D); less distinguishable intramural lesions
Figure 2 Distribution and Percentage of Typical and Atypical La
(A) Comparison of the percentage of patients with infarct-typical contrast-enhance
dial infarction in all 3 transplant coronary artery disease (TCAD) groups. Note the s
was at least 25% to 50%. (B) Comparison of the percentage of patients with infar
MRI the presence of CE-MRI was evenly distributed among the groups. LE  late eFig. 1E); or infero-septal sharply circumscribed lesions of
elayed CE-MRI (Fig. 1F).
Mean infarct-typical myocardial mass was 3.2% for
CAD I, 4.1% for TCAD II, and 9.9% for TCAD III
p  0.05).
istribution and percentage of CE-MRI in TCAD I
o III. As shown in Figure 2A, 5 TCAD I (23%), 4
CAD II (33%), and 6 TCAD III (84%) patients had
nfarct-typical CE-MRI lesions. Interestingly, even in
atients with TCAD I having inconspicuous angiogra-
hies, nearly every fourth patient revealed typical MI
E-MRI patterns.
Transmural infarcts were present in TCAD I to III, whereas
1% to 75% CE-MRI could be seen in TCAD I  III and
6% to 50% CE-MRI lesions were observed in TCAD II 
II. Less than 25% transmural extent of CE-MRI was not
resent in any of the groups.
nhancement in TCAD I to III
netic resonance imaging (CE-MRI) and their distribution and murality of myocar-
ant increase of infarct-typical lesions from TCAD I to III. The transmurality index
ical CE-MRI and their distribution in all 3 TCAD groups. For infarct-atypical CE-
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September 30, 2008:1160–7 MRI Characterization of Patients After HTXGenerally, an increasing number of patients with infarct-
ypical CE-MRI patterns could be observed with increasing
everity of TCAD.
Spotted and intramural CE-MRI was evenly present in
CAD I to III (50% vs. 58% vs. 42%, p  NS), whereas
nferoseptal and diffuse patterns could be observed only in
CAD I  II (Fig. 2B).
istribution of infarct-typical/-atypical CE-MRI in the
HA 17-segment model. Figure 3 displays the distribu-
ion of all affected infarct-typical and -atypical CE-MRI
egments related to the AHA 17-segment model. In gen-
ral, of 27 affected infarct-typical segments, 22 (81%) were
ccentuated in the mid-ventricular (segments VII to XII)
nd apical (XIII to XVII) segments. Only 5 infarcts (19%)
ere observed at basal slices.
In contrast, of 50 affected infarct-atypical segments, the
verall majority of 30 segments (60%) were accentuated at
asal slices (segments I to VI) and only 20 atypical CE-
RI patterns (40%) were observed in mid-ventricular and
pical slices (VII to XVII).
yocardial function and mass in infarct-typical, infarct-
typical, and combined CE-MRI. To further investigate
he effects of MI on cardiac function and mass, HTX
Figure 3 Distribution Patterns of Infarct-Typical and -Atypical C
Distribution of all affected infarct-typical (A) and -atypical (B) contrast-enhanced m
tion 17-segment model. Of infarct-typical lesions, 81% were accentuated in the mi
infarct-atypical areas were accentuated at basal slices, predominantly lateral and
yocardial Function and Mass in Infarct-Typical, Infarct-Atypical, a
Table 2 Myocardial Function and Mass in Infarct-Typical, Infarc
Infarct-Typical CE-MRI
(n  6)
Infarct-Aty
(n
EF (%)  SD 45 16 66
EDV (ml)  SD 148 27 139
ESV (ml)  SD 81 27 47
SV (ml)  SD 64 28 92
Myocardial mass (g)  SD 100 17 98E-MRI  contrast-enhanced magnetic resonance imaging; EDV  end-diastolic volume; EF  ejection fratients have been categorized into: 1) infarct-typical; 2)
nfarct-atypical; and 3) combined infarct-typical and
atypical CE-MRI independent of their prior angiographi-
ally assessed degree of TCAD (Table 2).
Compared with patients with atypical or combined CE-
RI, patients with typical infarcts showed significantly
ower ejection fractions (45  16% vs. 66  6% and 60 
3%) and significantly higher EDV (148  27 ml vs. 139 
2 ml vs. 164  43 ml, p  0.05) and ESV (81  27 ml vs.
7 15 ml and 69 38 ml). Differences in stroke volume and
yocardial mass failed to reach statistical significance. Com-
aring combined with only infarct-atypical CE-MRI patients,
he difference for EF and ESV also proved to be statistically
ignificant (both p  0.05).
iscussion
issue characterization with CE-MRI allows an earlier
dentification of TCAD, even in the absence of angio-
raphic changes. Accordingly, we detected infarct-typical
E-MRI areas suggesting silent MI in an apparently
vent-free HTX cohort.
I
c resonance imaging (CE-MRI) segments related to the American Heart Associa-
icular (segments VII to XII) and apical (XIII to XVII) segments. In contrast, 60% of
. *Segment XVII.
ombined CE-MRI
pical, and Combined CE-MRI
CE-MRI Combined CE-MRI
(n  9) p Value Significance
60 13 0.035 Yes
164 43 0.05 Yes
69 38 0.045 Yes
85 34 0.145 No
117 34 0.24 NoE-MR
agneti
d-ventr
inferiornd C
t-Aty
pical
 12)
 6
 32
 15
 21
 21action; ESV  end-systolic volume; SV  stroke volume.
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MRI Characterization of Patients After HTX September 30, 2008:1160–7revalence and distribution of infarct-typical CE-
RI. We found that infarct-typical CE-MRI was already
resent in about one-fourth of TCAD I and one-third of
CAD II patients with significant differences (p  0.05)
etween the groups.
Because the transplanted hearts were echocardiographi-
ally classified as free of previous MI, it is tempting to
peculate that these patients had suffered silent subclinical
I after HTX and might have been missed by routine
oronary angiography because corresponding angiograms in
CAD I showed no or only mild narrowing of epicardial
rteries.
In the earlier stages of TCAD, the narrowing of the
ntima is more likely to cause microinfarctions, whereas a
ore advanced coronary affection might also result in
arger infarcts. Consistently, we found single small
nfarct-typical CE-MRI patterns in TCAD I and mul-
iple late enhancement lesions of variable size in TCAD
I and III.
Infarct-typical segments were more often found in mid-
entricular and apical segments. This observation is consis-
ent with the angiographic appearance of TCAD showing
redominantly subsegmental rarefication of coronary arter-
es (19). Due to the diffuse concentric affection of the entire
oronary artery, smaller vessels are more prone to occlusion
han larger branches (19,20).
As proposed by Glagov et al. (7), in common atheroscle-
osis luminography does not represent the intramural
tate of the inflammatory atherosclerotic process, because
ositive coronary arterial remodeling or vessel wall thick-
ning are only detected by IVUS (20). Therefore, non-
nvasive tissue characterization by CE-MRI would
reatly enhance our knowledge of the vascular TCAD
ffection in HTX patients.
Our observations highlight the importance of MRI as a
omplementary tool in the follow-up of HTX. Because MI
n HTX patients is associated with major adverse cardiac
vents and poor prognosis (1,2), 22% of TCAD I patients
ith already subsided MI would have been overlooked or
isclassified by fluoroscopy angiography. However, further
linical studies are needed to show the correlation between
he existence or severity of CE-MRI lesions and adverse
linical outcomes.
The presence of infarct-typical CE-MRI was associated
ith a significantly worse LV function and higher EDV and
SV. Also, levels for NT-proBNP among all 3 TCAD
roups were significantly elevated, although creatinine levels
ere not dissimilar between groups.
Because LV function and volume as well as elevated
T-proBNP levels have a future prognostic relevance in
ontransplanted cardiac patients, one might hypothesize
bout the role of NT-proBNP in this patient collective.
iven that NT-proBNP levels correlate with the TCAD
tage, it is reasonable to presume that NT-proBNP levels
ould serve as an independent predictor of advanced TCAD cdata on file, not shown) and could also be useful to rule out
dvanced TCAD stages.
revalence and distribution of infarct-atypical CE-
RI. Infarct-atypical CE-MRI was found in approxi-
ately 50% of all cases, suggesting that fibrosis was evenly
istributed across all TCAD stages.
By its visual appearance, infarct-atypical CE-MRI could
e described as diffuse, spotted, intramural, or localized
antero-/inferoseptal) without colocalization to specific cor-
nary territories.
In our patient cohort, no correlation was found between
typical CE-MRI and the different TCAD stages. The
xact patho-mechanism for the occurrence of infarct-
typical CE-MRI patterns is yet unclear. Potential reasons
nclude presence of end-stage renal disease (21), the amount
f organ rejections or pharmacological interventions against
rgan rejections, cytomegalovirus or other opportunistic
nfections, former myocarditis (22), or other immune pro-
esses (23). In our study we could not conclusively demon-
trate whether the missing correlation between atypical late
nhancement and organ rejections or immunosuppressive
nterventions was only due to small sample size or whether
ny of the numerated factors played a significant role in the
eneration of myocardial enhancement patterns. Again,
urther studies with larger patient numbers are needed to
valuate this lack of correlation more in depth, potentially
mploying targeted biopsies in combination with immuno-
istological techniques.
Infarct-atypical distribution patterns were predominantly
etected in basal and mid-ventricular areas. Predominantly
hese areas are prone to infarct-atypical CE-MRI patterns
ith histologically proven storage of pathologic proteins, as
s known from storage diseases such as amyloidosis (24),
nderson-Fabry disease (25), or other glycogen storage
iseases (26). Whether a comparable patho-mechanism
ould also be responsible for similar CE-MRI patterns in
TX patients is yet unknown and warrants further
nvestigation.
In our study we employed 0.2 mmol/kg bodyweight
adolinium for the myocardial tissue characterization. Be-
ause chronic renal disease was prevalent in most patients
nd since only recently there is convincing evidence that
adolinium contrast agents could be linked to nephrogenic
ystemic fibrosis (27), restrictive contrast agent administra-
ion would be mandatory. Also, potentially nephrotoxic
edication should be discontinued before MRI, the patient
hould be well hydrated, creatinine levels should be followed
p, or even hemodialysis after MRI should be considered
28,29).
tudy limitations. This pilot study described CE-MRI
bnormalities in a well-defined HTX population and was
either intended nor powered to evaluate the prognostic role
f magnetic resonance abnormalities.
The stage of TCAD might have been underestimated by
he use of coronary angiography instead of IVUS. However,
oronary angiography is more commonly used in clinical
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ion for TCAD.
No correlation was found between atypical CE-MRI and
rgan rejections, immunosuppressive therapies, infections,
yocarditis, or renal impairment (23). Further studies with a
arger sample size and targeted myocardial biopsies are needed
o investigate potential underlying pathological mechanisms.
The high rate of suboptimal imaging quality (approxi-
ately 20%) in contrast to previously published data re-
ected our intention to reduce selection bias by inclusion of
onsecutive patients. We did not exclude patients with
hythm and conductance disorders. As a consequence, our
esults might underestimate the true prevalence of atypical
nd to a lesser degree typical enhancement due to poorer or
oninterpretable image quality.
onclusions
E-MRI allowed identification of silent MI in an appar-
ntly event-free HTX population and was able to disclose
yocardial fibrosis already in patients with absent or mild
ngiographic TCAD. Because subtle MI and beginning
icrovascular dysfunction might be missed with conven-
ional coronary angiography, CE-MRI could be helpful to
stablish an earlier diagnosis and to intensify medical
reatment. Future studies are necessary, however, to test
rognostic implications associated with CE-MRI patterns.
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